Pyrazinamide-Induced Urticaria and Angioedema: a Case Report.
10.3904/kjm.2018.93.3.306
- Author:
Yewon KANG
1
;
Jieun KANG
;
Kyoungmin LEE
;
Dae Hyun JEONG
;
Soomin NOH
;
Bomi SEO
;
Tae Bum KIM
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Pyrazinamide;
Drug hypersensitivity;
Angioedema
- MeSH:
Angioedema*;
Dizziness;
Drug Hypersensitivity;
Edema;
Ethambutol;
Exanthema;
Female;
Humans;
Hypersensitivity, Delayed;
Hypersensitivity, Immediate;
Hypotension;
Isoniazid;
Middle Aged;
Prescriptions;
Prevalence;
Pyrazinamide;
Rifampin;
Tuberculosis;
Tuberculosis, Lymph Node;
Tuberculosis, Pulmonary;
Urticaria*
- From:Korean Journal of Medicine
2018;93(3):306-310
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pyrazinamide (PZA) is an anti-tuberculosis drug and an essential component of the standard four-drug regimen for tuberculosis. Here, we report a case of immediate angioedema secondary to PZA administration intended for pulmonary tuberculosis treatment. A previously healthy 48-year-old woman was diagnosed with pulmonary tuberculosis and tuberculous lymphadenitis. Thirty minutes after taking the first dose of isoniazid, rifampicin, pyrazinamide, and ethambutol, the patient developed facial edema, generalized rash, and dizziness. An oral provocation test was performed on the four drugs, and 1,000 mg pyrazinamide showed a positive result characterized by 50 minutes of urticaria, angioedema, and hypotension. As the prevalence of tuberculosis increases, prescriptions for anti-tuberculosis drugs may increase as well. Clinicians should be aware of the possibility of immediate hypersensitivity as well as delayed hypersensitivity to anti-tuberculosis drugs.
